$6,799.00
In Stock
Puma Biotechnology’s Nerlynx was recently approved by the FDA for extended adjuvant treatment of HER2-positive early-stage breast cancer. It is the first drug for extended adjuvant treatment for patients with this pathology, allowing to reduce the risk of recurrence.
Active ingredient: neratinib
Prescription medicine
